Per-operative COVID-19 modifications for oculoplastic service: patients perspective and regional review of practice of a protective draping technique.

Purpose: COVID-19 has posed problems for oculoplastic surgeons. One issue we felt needed to be addressed was the way patients are draped for surgery. Traditionally patients are draped with their full face exposed, and as a result, aerosols generated from both the patient and surgical team put the other party at risk.

Imagining an Orientation Built on Trust.

To streamline competency assessment documentation during orientation, we developed a comprehensive, three-phase plan, consisting of a tiered skills acquisition model, entrustable professional activities, and the full incorporation of Donna Wright's recommendations for initial competency development, allowing for the transition away from the traditional skills checklist (Wright, 2005). We were able to reduce orientation time and preceptor confusion while increasing orientation process satisfaction by the end of our revisions.

Physical educators' beliefs and self-reported behaviors toward including students with autism spectrum disorder.

With an increase in the presence of students with autism spectrum disorder (ASD) in the general physical education (GPE) classroom, understanding the current state of GPE teachers' beliefs and behaviors for including these students is warranted. The current study aimed to examine the beliefs and self-reported behaviors of GPE teachers' inclusion of students with ASD. In addition, the study examined potential factors affecting their inclusion behaviors.

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC) activity. We evaluated methods to detect changes in chloride and sodium transport by NPD based on a secondary analysis of a Phase II CFTR-modulator study. Thirty-nine subjects with CF who also had the G551D-CFTR mutation were randomized to receive ivacaftor (Kalydeco™; also known as VX-770) in four doses or placebo twice daily for at least 14 days.